Halyk Finance's trading idea: Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. – is an American biopharmaceutical company specializing in the development of treatments for neurological, hormonal, and psychiatric diseases with high unmet medical needs. The company's operations focus on the commercialization of orphan and specialty drugs, with INGREZZA for the treatment of tardive dyskinesia and the recently launched CRENESSITY serving as the primary revenue drivers. In May 2026, the company significantly scaled its business and expanded its rare endocrine disease portfolio through the strategic acquisition of Soleno Therapeutics for $2.9 billion. The investment profile is supported by sustainable growth in commercial product sales, high margins in the specialty portfolio, and a promising clinical pipeline, including Phase 3 drugs for treating major depressive disorder and schizophrenia.

Growth drivers:

• Structural underpenetration of the VMAT2 inhibitor market
• Scaling the Crenessity orphan franchise
• Portfolio diversification through M&A
• Addressable population of schizophrenia and major depressive disorder (MDD)
• Dual M&A strategy
• Late-stage clinical pipeline
• Temporary protection from Medicare pricing pressure
• Patent horizon